Short answer
Eton Pharmaceuticals, Inc. (ETON) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). ET-700 showed better tolerability: treatment-related adverse events in 1 of 12 participants versus 8 of 12 for GALZIN.
Eton Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- ET-700 showed better tolerability: treatment-related adverse events in 1 of 12 participants versus 8 of 12 for GALZIN
- Copper absorption inhibition was weaker: hepatic copper uptake decreased 12% with ET-700 versus 46% with GALZIN
- Placebo showed an 11% increase in hepatic copper uptake in the prespecified primary analysis
- Additional faster-release ET-700 formulations planned for 2027 studies, creating development opportunity but requiring efficacy improvement
Item EX-99.1 · Exhibit EX-99.1
- Preliminary ET-700 study showed treatment-related adverse events in 1 of 12 participants, versus 8 of 12 for GALZIN
- Gastrointestinal event rate 0.30 per 100 participant-days for ET-700, versus 5.35 for GALZIN and 0.89 for placebo
- Hepatic copper uptake declined 12% with ET-700, versus 46% with GALZIN and an 11% increase with placebo
- GALZIN outperformed ET-700 on copper uptake in the 35-participant intention-to-treat analysis, p=0.023
- Additional faster-release ET-700 formulations planned for 2027, targeting stronger copper inhibition while preserving tolerability
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Eton Pharmaceuticals, Inc. 8-K filings
Get the next ETON 8-K as it lands
Follow ETON for push alerts, or ask the research agent what this filing means.